Clinical Studies

NYX-2925

Phase 2 – Painful Diabetic Peripheral Neuropathy

A randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of NYX-2925 in subjects with painful diabetic peripheral neuropathy — For more information, visit www.clinicaltrials.gov

Phase 2 – Fibromyalgia

A randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of NYX-2925 in subjects with fibromyalgia — For more information, visit www.clinicaltrials.gov

NYX-783

Phase 2 – Post-Traumatic Stress Disorder

A randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of 50 mg NYX-783 once daily vs. placebo in participants with post-traumatic stress disorder (PTSD) — For more information, visit www.clinicaltrials.gov

A Phase 2 study evaluating 150 mg NYX-783 once daily in PTSD is on track for initiation in the first quarter of 2022.

NYX-458

Phase 2 – Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

A first-in-patient, randomized, double-blind, placebo-controlled study to evaluate NYX-458 in subjects with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies — For more information, visit www.clinicaltrials.gov